Search

Your search for "180 Life Sciences" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Medical Advisory Board Chair Coauthors Review of Early Stage Dupuytren’s Disease Treatment

January 25, 2023

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has announced the publication of a review written by Professor Jagdeep Nanchahal, chair of ATNF’s medical advisory board; the review was also written by a colleague of Nanchahal’s from the University of Oxford. Titled “Treatments for early stage Dupuytren’s disease: An evidence-based approach,” the article was […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Engages Kinexum for Assistance in MAA Submission

January 17, 2023

180 Life Sciences (NASDAQ: ATNF) today announced its engagement of Kinexum, a strategic advisory firm, to support the company in submitting a Marketing Authorisation Application (“MAA”) for adalimumab to treat progressive early-stage Dupuytren’s disease. According to the announcement, the MAA will be submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA” or […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Is Notified by NASDAQ Exchange of Full Compliance

January 5, 2023

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has regained full compliance with NASDAQ minimum-bid price requirements. The company received a letter from the NASDAQ Stock Market LLC providing notification of the change in status; the letter was dated Jan. 4, 2023. According to the letter, the exchange determined that the closing bid price […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Review on Molecular Basis of Dupuytren’s Disease

January 4, 2023

180 Life Sciences (NASDAQ: ATNF) today announced the publication of a review entitled “Dupuytren’s disease: a localized and accessible human fibrotic disorder” in the journal Trends in Molecular Medicine. In the article, the authors at the University of Oxford, led by Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, describe […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Shareholder Letter with Corporate Update

December 29, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released a letter to shareholders; the letter is signed by CEO James Woody. In the letter, Woody notes that the company’s priority continues to be its clinical programs, repurposing anti-tumor necrosis factor (“TNF”) drugs for the treatment of Dupuytren’s disease, frozen shoulder and post-operative delirium. […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on Registered Direct Offering for $6M

December 27, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced registered direct offering. The offering, which was with a single healthcare-focused U.S. institutional investor, was comprised of 1,714,286 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,571,429 shares of […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enters into Registered Direct Offering Agreement for $6M Proceeds

December 21, 2022

  180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor. The agreement is for a registered direct offering to include the purchase and sale of 1,714,286 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Status Update on MHRA Interaction

December 1, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, is sharing an update on its efforts to seek marketing authorization from Medicines and Healthcare Products Regulatory Agency (MHRA) for Anti-TNF treatment of early-stage Dupuytren’s Contracture. ATNF officials, along with representatives from the company’s regulatory consultants from the United States and the United Kingdom, met with […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Participation in Upcoming Biotech Conference

November 21, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, will be participating in A.G.P.’s Virtual Biotech Conference. The conference is scheduled for Nov. 30–Dec. 1, 2022. According to the announcement, ATNF president and CEO Dr. James Woody will present […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Adalimumab Has Promise as Treatment for Early-Stage Dupuytren’s Disease

November 15, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has announced that adalimumab, its anti-TNF treatment, has shown potential to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease. According to the announcement, researchers at Oxford Population Health’s Health Economics Research Centre and the Kennedy Institute of Rheumatology have identified the potential; adalimumab […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

September 26, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain on track with clinical development plans. “Currently, we have an active clinical development program that includes phase 2a and phase […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enrolls First Patient in Early-Stage Frozen Shoulder Trial

August 22, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, is noting a significant milestone reached in a key clinical trial designed to evaluate anti-tumor necrosis factor (“TNF”) for patients with early-stage, pain predominant frozen shoulder. The company announced that the first patient has been randomized in the trial, which is funded by UK-based National Institute […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Grant Award to the University of Oxford to Conduct Anti-TNF Therapy Trial

July 27, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced that a team led by researchers at University of Oxford were awarded a grant from the National Institute for Health and Care Research (“NIHR”) in the U.K. to conduct a feasibility trial. The trial will investigate whether anti-tumor necrosis factor (“TNF”) therapy, administered at […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Secures $6.5M in Registered Direct Offering

July 21, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced the closing of its registered direct offering to a single health care-focused U.S. institutional investor. The offering consisted of 6,132,076 shares of the company’s common stock (including common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common stock […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $6.5M Registered Direct Offering

July 18, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced its entry into a definitive agreement with a single health care-focused U.S. institutional investor, for the purchase and sale of 6,132,076 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Issues Letter to Stockholders

June 23, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody provides an update on the company’s plans for developing a novel therapy for patients with early-stage Dupuytren’s disease, “Our overall aim continues to be to develop new, […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Shares Status of Anti-TNF Treatment, Responses from MHRA and FDA

June 15, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has shared progress status on the company’s anti-TNF treatment, adalimumab, designed to treat early-stage Dupuytren’s disease. The company has reached out to the U.K. Medicines and Healthcare products Regulatory Agency […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Initiates Formal Discussions with UK and US Regulatory Authorities Following Promising Dupuytren’s Trial

May 31, 2022

180 Life Sciences (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The company today announced that, following publication of promising data from a phase 2b Dupuytren’s trial in the June 2022 issues of The Lancet Rheumatology, 180 Life Sciences […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Report Positive Results of Dupuytren’s Disease Study

May 2, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has published the final results of its phase 2b study of patients with Dupuytren’s disease. The results were published in “The Lancet Rheumatology.” According to the announcement, highlights of the report […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Scientific Advisory Board

February 17, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has formed a scientific advisory board (“SAB”). Initial board members include the following: Dr. Raphael Mechoulam from the Hebrew University in Israel; Dr. Kevin Tracey from Hofstra/Horthwell in the United States; […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Shareholders from CEO Dr. James Woody

January 31, 2022

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released a letter to shareholders from its Chief Executive Officer James Woody, MD, PhD. In the letter, Dr. Woody commented on the company’s current share price, indicating that […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Participation in Biotech Showcase 2022 Virtual Conference

December 28, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, will be participating in next year’s Biotech Showcase 2022 Virtual Conference. The online event is scheduled for Jan. 10–12, 2022. As part of the company’s participation, ATNF CEO and president […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces License Agreement with University of Oxford

December 15, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has entered into a license agreement with the University of Oxford. The exclusive global agreement outlines planned development and commercialization of HMGB1, a regenerative molecule for promoting liver repair and […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Additional Info Regarding Successful Dupuytren Phase 2b Clinical Trial Results

December 6, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has shared follow-up information regarding its phase 2b clinical trial for Dupuytren’s disease; initial results were announced on Dec. 1, 2021. The study was conducted in partnership with Oxford University. […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Co-Founder Presents Keynote Address at 2021 International Dupuytren Symposium

December 1, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Professor Jagdeep Nanchahal from the University of Oxford, a co-founder of 180 Life Sciences, presented a keynote address at the 2021 International Dupuytren Symposium on Wednesday, […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Receives Grants of New Patents Through Licensing Agreement

November 22, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, is growing its patent portfolio. The company announced that the Yissum Research Development Company of the Hebrew University has received grants of two new patents, one in the United States […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Co-Founder to Keynote at 2021 International Dupuytren Symposium

November 18, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Professor Jagdeep Nanchahal from the University of Oxford, a co-founder of 180 Life Sciences, will present a keynote address at the 2021 International Dupuytren Symposium. The […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Strategic Appointment of Quan A. Vu

November 3, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced it has named Quan A. Vu to the role of chief operating officer/chief business officer. Vu is a highly versatile and accomplished strategy, corporate/business development, finance and […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Preclinical Report on the CBG Impact on Pain, Inflammation, Obesity

October 26, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has published a preclinical study report on the effects of cannabigerol (“CBG”) derivatives on pain, inflammation and obesity. The report  was published in the “Molecules” journal. ATNF has worked closely with […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Continues to Expand Portfolio, Pipeline and Patient Access to Innovative Therapies

September 30, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its receipt of a Notice of Allowance from the United States Patent and Trade Office for application 16/661,769 “Method for Reducing Post-Operative Cognitive Dysfunction (‘POCD’).” According to […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF), Celltrion Healthcare Enter MOU for Strategic Supply Agreement

September 20, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its entry into a memorandum of understanding (“MOU”) with Celltrion Healthcare, a leading biopharmaceutical company. The MOU is for the supply of an anti-TNF biosimilar drug used […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Releases Letter to Stockholders

August 30, 2021

180 Life Sciences (NASDAQ: ATNF) CEO Dr. James Woody issued a letter to stockholders of the clinical-stage biotechnology company that has its lead indication in phase 2b clinical trial and is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The letter noted that the company has […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes $15M Private Placement

August 24, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has closed its previously announced private placement of 2,500,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,500,000 shares of common stock […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $15M Private Placement

August 19, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into securities purchase agreements with certain institutional investors. The intent is to raise approximately $15.0 million through the private placement of 2,500,000 shares […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Chair to Present Keynote at Autumn Scientific Meeting of BSSH

August 2, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that board chairman Jagdeep Nanchahal will be presenting the keynote address at the upcoming British Society for Surgery of the Hand (“BSSH”) meeting. The meeting will be held […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Participate at BTIG Virtual Biotechnology Conference

July 29, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its plans to participate at the BTIG Virtual Biotechnology Conference being held from Aug. 9-10, 2021. ATNF’s CEO Dr. James Woody and Professor Jagdeep Nanchahal, chairman of […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Selects Lead Synthetic CBD Analogue

July 28, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has selected a lead synthetic CBD analogue that is expected to move forward in clinical development for both inflammation and pain. According to the update, […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Regains Compliance with Nasdaq Listing Rule 5250(c)(1)

July 20, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has regained Nasdaq compliance under listing rule 5250(c)(1). As previously disclosed in the current report on Form 8-K, filed by 180 Life Sciences with the […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Regains Compliance with Nasdaq Listing Rules

July 12, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has regained Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2). As previously disclosed on the January 2021 report on Form 8-K, the Listing Qualifications Department […]

InvestorNewsBreaks

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Expansion of Scientific Fibrosis Platform

July 7, 2021

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that “Collagen VI as a driver and disease biomarker in human fibrosis” was published in the FEBS Journal as part of its State-of-the-Art Review series. The piece […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).